TITLE

Bacteria-Triggered Reactive Arthritis: Implications for Antibacterial Treatment

AUTHOR(S)
Toivanen, A.
PUB. DATE
February 2001
SOURCE
Drugs;Feb2001, Vol. 61 Issue 3, p343
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reactive arthritis (ReA) is definitely caused by an infection. Several observations suggest that the triggering microbe may persist in the tissues of the patient for a prolonged time. The obvious conclusion is to consider antibacterial treatment. In two instances antibacterial agents are of definite value: in the primary and secondary prevention of rheumatic fever and for early eradication of Borrelia burgdorferi in order to prevent development of the arthritis associated with Lyme disease. Altogether, clinical and experimental data exist to indicate that if antibacterial treatment of ReA can be started very early during the pathogenetic process, the disease can be prevented or the prognosis improved. In fully developed ReA, the value of antibacterial agents is less certain. All available evidence indicates that short term antibacterial treatment has no effect on the prognosis and final outcome of ReA, and the results with long term administration of antibacterials are also overall poor. In some instances sulfasalazine appears useful, rather as a result of its antirheumatic effect or influence on an underlying inflammatory bowel disease than its action as an antibacterial agent. Tetracyclines have also been found to have an effect on ReA, but again, this is probably due to their anti-inflammatory action rather than any antibacterial effect.
ACCESSION #
4308084

 

Related Articles

  • A painful market. Hewitt, Allison // Pharmaceutical Executive;Oct97, Vol. 17 Issue 10, p120 

    Reports on the availability of the IMS report entitled `National Disease and Therapeutic Index MarketView 97, Arthritis and Antiarthritic Therapy' which offers a comprehensive analysis of key factors, such as market size and trends, by patients, visit and treatment cost. Order information.

  • Acute Monoarthritis: A Practical Approach to Assessment and Treatment. Towheed, Tanveer R. // American Family Physician;11/15/1996, Vol. 54 Issue 7, p2239 

    Presents approaches in the assessment and treatment of patients with acute monoarthritis. Most common causes of acute monoarthritis; Definition of acute monoarthritis; General principles in the management of patients with acute monoarthritis; Information on when a patient should be referred to...

  • `3 R's' can help arthritis suferrers to ease the pain.  // New York Amsterdam News;3/4/95, Vol. 86 Issue 9, p14 

    Suggests treatment for arthritis. Relaxation; Range of motion; Resistance.

  • Dateline Washington. Coorsh, Richard // Consumers' Research Magazine;Jul93, Vol. 76 Issue 7, p6 

    States an advisory panel of the Food and Drug Administration has rejected the idea of allowing the over-the-counter sale of naproxen, the nation's best-selling prescription drug for relieving arthritis inflammation and pain. The advisory panel has ruled that clinical trials do not provide...

  • What Is the Appropriate Treatment Course for Bacterial Arthritis in Children? Bradley, John S. // Clinical Infectious Diseases;5/1/2009, Vol. 48 Issue 9, p1211 

    The article reports on the appropriate treatment course for bacterial arthritis in children. It states that a heightened awareness of increasing antimicrobial resistance in pediatrics demands that a treatment course needs to both maximize efficacy and minimize antibiotic exposure to limit the...

  • Report on arthritis: 'a nation in pain,' an expanding market. Liebman, Milton // Medical Marketing & Media;Dec2002, Vol. 37 Issue 12, p19 

    Reports on the expansion of the drug market for arthritis in the U.S. Number of people suffering from the condition; Development of drugs to treat symptoms of arthritis; Increase funding for drug research.

  • Waiting times for knee arthroplasty. Gross, Michael // Canadian Journal of Surgery;Aug2002, Vol. 45 Issue 4, p247 

    Reports the assessment of waitlists for joint arthroplasty. Use of the Medication Quantification Score; Discrepancy between low volume and high volume surgeons; Treatment for patients with arthritis.

  • CLINICAL RESPONSES TO ETANERCEPT IN SYSTEMIC ARTHRITIS MEASURED BY 'CORE SET' OUTCOME VARIABLES.  // Archives of Disease in Childhood;Apr2003 Supplement, Vol. 88, pA37 

    Presents an abstract of the study 'Clinical Responses to Etanercept in Systemic Arthritis Measured by 'Core Set' Outcome Variables,' by K.M. Bailey and T.R. Southwood, presented at the 7th Spring Meeting of the Royal College of Paediatrics and Child Health.

  • A COMPARISON BETWEEN THE MANAGEMENT OF EARLY JUVENILE IDIOPATHIC ARTHRITIS (JIA) AT WEXHAM PARK HOSPITAL WITH THE PUBLISHED GUIDELINES BY THE BRITISH PAEDIATRIC RHEUMATOLOGY GROUP (BPRG).  // Archives of Disease in Childhood;Apr2003 Supplement, Vol. 88, pA38 

    Presents an abstract of the study 'A Comparison Between the Management of Early Juvenile Idiopathic Arthritis (JIA) at Wexham Park Hospital With the Published Guidelines by the British Paediatric Rheumatology Group (BPRG),' by F.E. Demetriadi and M.A. Hall, presented at the 7th Spring Meeting of...

  • American College of Rheumatology issues management guidelines for arthritis of the hip and knee. Hochberg, M.C.; Altman, R.D. // American Family Physician;2/15/1996, Vol. 53 Issue 3, p985 

    Presents management guidelines for arthritis of the hip and knee from the American College of Rheumatology. Nonpharmacologic and pharmacologic therapy; Risk factors for medication; Contact information.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics